Xencor Presents Pre-Clinical Data for Anti-CD19 Antibody at AACR Monrovia, Calif. – April 15, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, presented data from its anti-CD19 antibody program during the Annual Meeting of the American Association for Cancer Research

Xencor to Present New Data from CD19 Program at Upcoming Scientific Meetings Monrovia, Calif. – April 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical CD19 program for lymphoma and leukemias at the Annual Meeting of the

Xencor Appoints Industry Veteran David R. King as Chairman of its Board of Directors Monrovia, CA — March 19, 2008 — Xencor, Inc., a company developing protein and antibody therapeutics, today announced that it appointed David R. King as Chairman of its Board of Directors. To Xencor, Mr.

Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma Monrovia, Calif. – February 11, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, has initiated a Phase I clinical trial with its lead product candidate XmAb™2513 in patients with Hodgkin lymphoma (HL) and

Human Genome Sciences And Xencor Announce Antibody Collaboration ROCKVILLE, Maryland and MONROVIA, California – February 7, 2008 – Human Genome Sciences, Inc. (Nasdaq: HGSI) and Xencor, Inc. today announced a collaboration agreement under which Xencor will apply its proprietary XmAb™ humanization

Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology Monrovia, Calif. – January 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it received a patent from the United States Patent and Trademark Office (US 7,317,091 B1)

Xencor Data from Pre-clinical XmAb™ Antibody Studies Presented at American Society of Hematology Meeting Monrovia, Calif. – December 10, 2007 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today the presentation of results from pre-clinical studies evaluating two

Xencor Presents Findings on New Aspect of its Fc Technology Targeting Autoimmune Disease Monrovia, Calif. — December 7, 2007 — Xencor, Inc., a company developing protein and antibody therapeutics, presented findings at IBC Life Sciences’ 17th Annual Antibody Engineering Conference demonstrating the

Xencor Expands Series E Financing to $60 Million MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced that it raised an additional $15 million in an extension of its Series E financing, bringing the total raised in this round to $60

Jeffrey D. Bloss, M.D., Joins Xencor as Chief Medical Officer MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, a company developing protein and antibody therapeutics, today announced the appointment of Jeffrey D. Bloss, M.D., F.A.C.O.G., as chief medical officer. Dr.